NCT03092895View on ClinicalTrials.gov

A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC

PHASE2CompletedINTERVENTIONAL
Enrollment

157

Participants

Timeline

Start Date

April 27, 2017

Primary Completion Date

March 31, 2021

Study Completion Date

March 31, 2021

Conditions
Advanced Primary Liver CancerAdvanced Biliary Tract Carcinoma
Interventions
BIOLOGICAL

SHR-1210

Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks

DRUG

Apatinib

Subjects receive Apatinib orally every day with a dose escalation

DRUG

FOLFOX4

Subjects receive FOLFOX4 treatment every 2 weeks

DRUG

GEMOX

Subjects receive GEMOX treatment every 2 weeks

Trial Locations (7)

200003

Zhongshan Hospital, Shanghai

200032

Fudan University Shanghai Cancer Center, Shanghai

210002

81 Hospital Nanjing, Nanjing

230000

The Second Affiliated Hospital Of Anhui Medical University, Hefei

330006

The First Affiliated Hospital of Nanchang University, Jiangxi

410000

Hunan Cancer Hospital, Hunan

450008

Cancer Hospital of Henan province, Zhengzhou

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03092895 - A Study of SHR-1210 in Combination With Apatinib or Chemotherapy in Subjects With Advanced PLC or BTC | Biotech Hunter | Biotech Hunter